TORREY phase 2 study of seralutinib in pulmonary arterial hypertension (PAH): Circulating biomarkers of proliferation, inflammation and fibrosis improve with treatment
TORREY phase 2 study of seralutinib in pulmonary arterial hypertension (PAH): Circulating biomarkers of proliferation, inflammation and fibrosis improve with treatment
ATS – May 2024a
Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).
